Clinical Trial Update: AP5346 or Oxaliplatin in Treating Patients With Metastatic and/or Unresectable Recurrent Head and Neck Cancer [NA]

View source ↗

Summary

A clinical trial update notes UC San Diego is investigating AP5346 or oxaliplatin for metastatic and/or unresectable recurrent head and neck cancer; current sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• AP5346
• Eloxatin (oxaliplatin)

Snippet

Sponsor: University of California, San Diego | Conditions: Head and Neck Cancer | NA | Status: UNKNOWN